COSCIA MARTA

Personal Statement
I am a physician scientist with a broad background in Hematology, and specific training
and expertise in translational research. After obtaining my board certification in
hematology (2002), I spent a 2-year period as Visiting Scientist at National Cancer Institute
(NCI/NIH, Bethesda, MD, U.S.A.) (2002-2004), increasing my expertise on anti-tumor
immunotherapy and cancer vaccines in B-cell lymphoproliferative disorders. In 2007, I was
appointed Assistant Professor of Hematology at the University of Torino and Attending
Physician in Hematology at Città della Salute e della Scienza Hospital in Torino, Italy. In
2009, I obtained my PhD in Immunology and Cell Biology. In 2015, I established my own
research group focusing on the reciprocal interactions between the immune system, the
tumor microenvironment, and cancer cells in lymphoproliferative disorders. I was promoted
to Associate Professor in 2019. From 2020 to 2023, I served as Director of the
Postgraduate School of Hematology at the University of Torino. In May 2024, I was
appointed Associate Professor of Hematology at the University of Insubria and Director of
the Division of Hematology at Sette Laghi University Hospital in Varese, Italy. Since
October 2025, I have been serving as interim Director of the Division of Oncology at the
same institution. I am principal investigator of several research projects and clinical trials,
and I am member of the Board of the Working Party GIMEMA on chronic
lymphoproliferative disorders. I am lecturer and tutor in Hematology in the School of
Medicine, lecturer within the PhD program in Clinical and Experimental Medicine and
Medical Humanities and Director of the Postgraduate School of Hematology at the
University of Insubria.
Positions and employment
1998-2002 Post-doctoral fellow, Post-graduate School of Hematology, Department of

Medicine and Experimental Oncology, University of Torino.

2
2003-2004 Visiting Scientist hired by S.A.I.C. Inc., Experimental transplantation and
Immunology Branch, National Cancer Institute, National Institute of Health,
Bethesda, MA, U.S.A.

2007-2019 Assistant Professor, Department of molecular biotechnology and health

sciences, University of Torino

2007-2024 Staff physician, Division of Hematology, Città della Salute e della Scienza

University Hospital of Torino - Via Genova, 3 10126, Torino.

2015-2024 Group leader, Laboratory of Translational Hematology, Department of

Molecular Biotechnology and Health Sciences, University of Torino.

2019-2024 Associate Professor of Hematology, Department of Molecular Biotechnology

and Health Sciences, University of Torino.

2020-2023 Director of the Postgraduate School of Hematology, University of Torino
2024- Associate Professor of Hematology, Department of Medicine and Surgery,

University of Insubria, Varese, Italy.

2024- Director of the Postgraduate School of Hematology, University of Insubria,

Varese, Italy.

2024- Director of the Division of Hematology, Sette Laghi University Hospital,

Varese, Italy.

2025- Interim Director of the Division of Oncology, Sette Laghi University Hospital,

Varese, Italy.

Other Experience and Professional Records
1996-1998 Internship, Division of Hematology, University of Torino (clinical and research

activity).

2002-2003 Research fellow, Experimental transplantation and Immunology Branch,
National Cancer Institute, National Institute of Health, Bethesda, MA, U.S.A.

2005-2007 Research fellow, Division of Hematology, University of Torino.
2011 Training Course “Future Advances in Management Expertise” – Executive
management training program for specialists in onco-hematology (three
modules, two full days each), SDA Bocconi School of Management, Milan,
Italy.

2012 Training Course “Future Advances in Management Expertise” – executive
management training program for specialists in onco-hematology (one
module, two full days), SDA Bocconi School of Management, Milan, Italy.

2016 National Academic Qualification as Associate Professor
2023 National Academic Qualification as Full Professor
2025 Advanced Managerial Training Course for Directors of Healthcare Units

Honors and awards
2004-2005 Fellowship San Giovanni Battista Hospital, Torino, Italy (clinical and research

activity);

2005-2006 Fellowship “Fondazione Angela Bossolasco”, Torino, Italy (clinical and

research activity);

2005 Annual AIL (Italian Association against Leukemia) “Simona Drappo” award

for young researcher;

2006 Josè Carreras Foundation National award for young researchers;
2006-2007 Fellowship AIL (Associazione Italiana contro le leucemie- linfomi e mieloma)

(clinical and research activity).

2020- Member of the Scientific Committee in the Master Program Stem cells in
Regenerative Medicine and Cell Factory Management, University of Torino.

3
2021 Invited chairman of the oral abstract session on “Cellular immunotherapy and
gene therapy - Experimental” at the EHA2021Virtual Congress (June 9-17,
2021).

2021- Member of the Board of the Working Party GIMEMA on chronic
lymphoproliferative disorders (selected by the board of directors of the
GIMEMA Foundation).

Teaching employments
2007-2016 Lecturer on “Hematology” in the School of Medicine, University of Torino.
2007- Lecturer in the Post-graduate School of Hematology, University of Torino.
2010- Tutor within the Post-graduate School of Hematology, University of Torino.
2011-2015 Tutor within the Ph.D. Program in Life and Health Sciences, University of

Torino.

2014-2024 Member of the organizing committee of the Post-graduate School of

Hematology, University of Torino.

2019-2024 Lecturer of “Biotechnological therapies in Hematology” in the Biotechnology

course of the University of Torino.

2019-2024 Teacher of “Clinic and pathology of the hemolymphopoietic and immune

system” in the School of Medicine, University of Torino.

2020-2025 Lecturer in the Master Program II level - Stem cells in Regenerative Medicine
and Cell Factory Management (Modules on CAR T-cell therapy), University
of Torino.

2020-2022 Lecturer in the Post-graduate School of Allergology and Clinical Immunology,

University of Torino.

2020-2024 Lecturer in the Post-graduate School of Anesthesiology and Intensive Care,

University of Torino.

2021-2024 Lecturer in the Post-graduate School of Geriatrics, University of Torino.
2021-2024 Lecturer in the Post-graduate School of Radiotherapy, University of Torino.
2021-2024 Lecturer within the Ph.D. Program in Biomedical Sciences and Oncology,

University of Torino.

2022-2024 Teacher of “Clinical applications of diagnostic technologies in hematology” in
the School of Biotechnological and chemical sciences in diagnostics,
University of Torino.

2024- Teacher of Hematology in the School of Medicine, University of Insubria, Italy
2024- Director and member of the organizing committee of the Post-graduate

School of Hematology, University of Insubria.

2024- Teacher within the Ph.D. Program in Clinical and Experimental Medicine and

Medical Humanities, University of Insubria.

Clinical Research activity
Principal Investigator in >60 clinical trials investigating the role of new drugs for the
treatment of patients with chronic lymphocytic leukemia.
Professional Societies
- Italian Society of Hematology (SIE)
- Italian Society of Experimental Hematology (SIES)
- European Hematology Association (EHA)
- European Research Initiative on CLL (ERIC)

4

Editorial activity
- Peer reviewer for Journal of Cellular and Molecular Medicine, Cancer Immunology
Immunotherapy, European Journal of Hematology, Frontiers in Oncology, Frontiers
in Immunology, Oncotarget, Haematologica, Cancers, British Journal of Cancer,
Blood Reviews, Clinical and Translational Medicine, Lancet Hematology, Blood,
Hemasphere, Journal for ImmunoTherapy of Cancer, Leukemia&Lymphoma,
Leukemia.
- Review Editor for Frontiers in Oncology
- Editor for the special issue entitled “CAR T-Cell Therapies in Hematologic Tumors”
for the journal Frontiers in Oncology.
- Member of the editorial board of International Journal of Molecular Sciences
Scientific interests
- Translational and clinical studies in chronic lymphocytic leukemia, indolent
lymphomas and multiple myeloma
- Tumor-related immune dysfunctions and immunomodulatory properties of new
targeted drugs in chronic lymphocytic leukemia
- Tumor-microenvironment interactions and mechanisms of drug resistance
- Anti-tumor immunotherapy in chronic lymphocytic leukemia, multiple myeloma and
other lymphoproliferative disorders.
PEER-REVIEWED PUBLICATIONS
1. Laurenti L, Guglielmi F, Mosca A, Vitale C, Montalbano MC, Favrin G, Ferrarini I,
Galitzia A, Pasquale R, Moratti M, Catania G, Murru R, Giannarelli D, Martino EA,
Moia R, Zucchetto A, Tissino E, Autore F, Tomasso A, Stirparo L, Quaranta T, Abbate
PL, Gattei V, Gaidano G, Gentile M, Krampera M, Farina G, Visentin A, Innao V,
Varettoni M, Coscia M, Innocenti I. No lymphocytosis increase after cBTKi is a rare
phenomenon except for CD49d positive CLL mainly expressed in trisomy 12. Blood
Adv. 2026 Apr 2:bloodadvances.2025018640. doi:
10.1182/bloodadvances.2025018640. Epub ahead of print.
2. Molica S, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Albano F, Di Renzo
N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A,
Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A,
Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F,
Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Palma M, Arienti D, Mauro FR. Early
Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE
Study. Cancers (Basel). 2026 Mar 19;18(6):1000. doi: 10.3390/cancers18061000.
3. Fascì A, Vallone FE, Nabelsi N, Viry E, Sana I, Morabito A, Seghezzi S, Pesce NA,
Rovere M, Bertola N, Duculty C, Ravera S, Mouhssine S, Muzio M, Ghia P, Vitale C,
Coscia M, Moussay E, Gaidano G, Allan J, Furman RR, Paggetti J, Vaisitti T, Deaglio
S. Functional cooperation between the B-cell receptor and NOTCH1 in regulating
metabolic reprogramming in chronic lymphocytic leukemia. Leukemia. 2026 Mar 23.
doi: 10.1038/s41375-026-02912-7. Epub ahead of print.
4. Autore F, Visentin A, Vitale C, Giannarelli D, Fresa A, Morelli F, Mattiello V, Catania G,
Moia R, Quaresmini G, Giordano A, Scortechini I, Farina L, Sportoletti P, Gentile M,
Angeletti I, Innocenti I, Sanna A, Coscia M, Trentin L, Laurenti L. Clinical Outcomes in
Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy. Hematol Oncol.
2026 Mar;44(2):e70184. doi: 10.1002/hon.70184.

5
5. Cosentino C, Mouhssine S, Zucchetto A, Romano I, Salehi M, Cappelli LV, Iannelli F,
Almasri M, Maher N, Fumagalli L, Cardinali D, Visentin A, Nabki J, Cividini L, Al
Deeban B, Lazzaro M, Maiellaro F, Gaglio A, Perutelli F, Griggio V, Dondolin R, Bellia
M, Nicolosi M, Rasi S, Secomandi E, Caneparo V, Mahmoud AM, Deambrogi C,
Kogila S, Ghanej J, Nawabi MR, Del Giudice I, Albi E, Vitale C, Scarfò L, Coscia M,
Trentin L, Pileri S, Ghia P, Chiarle R, Gattei V, Terzi di Bergamo L, Rossi D, Foà R,
Gaidano G, Moia R. Dissecting clonal hematopoiesis in the myeloid compartment of
chronic lymphocytic leukemia and Richter transformation. Hemasphere. 2026 Feb
16;10(2):e70322. doi: 10.1002/hem3.70322.
6. Pighi C, Gasparetto A, Genuardi E, Tao J, Wang Q, Vitale C, Griggio V, Piazza R,
Ciavarella S, Coscia M, Ferrero S, Zamò A, Voena C, Chiarle R. Evaluation of the
Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors
in Chronic Lymphocytic Leukemia. Curr Issues Mol Biol. 2025 Dec 10;47(12):1031.
doi: 10.3390/cimb47121031.
7. Martino EA, Pitino A, Vigna E, Pasquale R, Ferrarini I, Moia R, Visentin A, Sanna A,
Motta M, Moratti M, Sportoletti P, Chiarenza A, Maggi A, Zammit V, Merli M, Innocenti
I, Giordano C, Nocilli L, Postorino M, Stelitano C, Ferrario A, Frustaci AM, Riva M,
Pepe S, Ibatici A, Scardino S, Anticoli Borza P, Ballotta L, Mancuso S, Malaspina F,
Mele A, Galimberti S, Catania G, Giordano A, Angeletti I, Schiattone L, Pennese E,
Miccolis RM, Fama A, Giordano G, Califano C, Bruzzese A, Caserta S, Farina G,
Bulian P, Loseto G, Pocali B, Innao V, Galieni P, Fraticelli V Sr, Vitale C, Romeo A,
Rossi M, Scortechini I, Vozella F, Malandruccolo L, Varettoni M, Morello L,
Pietrantuono G, Conte E, Cantelli M, Murru R, Caracciolo D, Derenzini E, Di Martina
V, Marasca R, Del Principe MI, Figuera A, Angotzi F, Coscia M, Di Renzo N, Laurenti
L, Amodio N, Musto P, Di Raimondo F, Liso A, Tedeschi A, Trentin L, Gaidano G,
Mauro FR, Tripepi G, Morabito F, Gattei V, Gentile M. Real-World Safety and
Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian
Cohort. Blood Adv. 2026 Jan 7:bloodadvances.2025018757. doi:
10.1182/bloodadvances.2025018757.
8. Vigna E, Martino EA, Pitino A, Pasquale R, Ferrarini I, Moia R, Visentin A, Sanna A,
Motta M, Moratti M, Sportoletti P, Chiarenza A, Maggi A, Zammit V, Merli M, Innocenti
I, Giordano C, Nocilli L, Postorino M, Stelitano C, Ferrario A, Frustaci AM, Riva M,
Pepe S, Ibatici A, Scardino S, Borza PA, Ballotta L, Mancuso S, Malaspina F, Mele A,
Galimberti S, Catania G, Giordano A, Angeletti I, Schiattone L, Pennese E, Miccolis R,
Fama A, Giordano G, Califano C, Bruzzese A, Caserta S, Farina G, Bulian P, Loseto
G, Pocali B, Innao V, Galieni P, Fraticelli V, Vitale C, Romeo A, Rossi M, Scortechini I,
Vozella F, Malandruccolo L, Varettoni M, Morello L, Pietrantuono G, Conte E, Cantelli
M, Murru R, Caracciolo D, Derenzini E, Martina VD, Marasca R, Principe MID, Figuera
A, Angotzi F, Coscia M, Renzo ND, Laurenti L, Amodio N, Musto P, Raimondo FD,
Liso A, Tedeschi A, Trentin L, Gaidano G, Mauro FR, Tripepi G, Corsonello A,
Morabito F, Gattei V, Gentile M. Clinical Frailty Scale as a Predictor of Early Treatment
Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With
Zanubrutinib: A Multicenter Real-World Study. Hematol Oncol. 2026
Jan;44(1):e70166. doi: 10.1002/hon.70166.
9. Cristinelli C, Merli M, Lucioni M, Gotti M, Sciarra R, Rattotti S, Carpi F, Favrin G,
Bianchi B, Neri G, Coscia M, Gambacorta M, Passamonti F, Paulli M, Arcaini L.
Clinical Presentation, Treatment, and Outcomes of 28 Patients With Castleman
Disease: A Retrospective Analysis of an Italian Cohort. EJHaem. 2025 Nov
6;6(6):e70158. doi: 10.1002/jha2.70158.

6
10. Vitale C, Ferrario A, Zamprogna G, Coscia M. Autoimmune Cytopenias in Chronic
Lymphocytic Leukemia. Hematol Oncol Clin North Am. 2025 Jun 30:S0889-
8588(25)00064-4. doi: 10.1016/j.hoc.2025.05.002.
11. Frustaci AM, Galitzia A, Lucignano M, Appio L, Olivieri J, Sanna A, Baraté C, Pane F,
Schiattone L, Casadei B, Ferrarini I, Figuera A, Sportoletti P, Loseto G, Stelitano C,
Visentin A, Celli M, Mauro FR, Palombi M, Coscia M, Innao V, Moia R, Motta M,
Russo F, Tani M, Arcari A, Boccellato E, Borella C, Capochiani E, Ferrari A, Gentile M,
Giachetti R, Giordano A, Bullo M, Lista E, Malandruccolo L, Musso M, Varettoni M,
Vozella F, Cibien F, Merli M, Nocilli L, Pasquini MC, Romeo AA, Rossi V, Turri G,
Vanazzi A, Cavaliere M, Gozzetti A, Crucitti L, Lucesole M, Deodato M, Tomasso A,
Zappaterra A, Murru R, Patti C, Laurenti L, Tedeschi A. Rethinking the feasibility and
safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional
factors may play a role in clinical practice. Haematologica. 2025 Jun 26. doi:
10.3324/haematol.2025.287799. Epub ahead of print.
12. Pepe S, Vitale C, Giannarelli D, Visentin A, Sanna A, Frustaci AM, Olivieri J, Quaglia
FM, Gozzetti A, Sportoletti P, Murru R, Innocenti I, Reda G, Pupo L, Levato L,
Porrazzo M, Ilariucci F, Moia R, Foglietta M, Rigolin GM, Chiurazzi F, Trastulli F,
Cellini A, Deodato M, Martino E, Laurenti L, Coscia M, Cuneo A, Gaidano G, Rossi D,
Gentile M, Mauro FR. Richter transformation in diffuse large B-cell lymphoma in
patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and
outcomes. Leukemia. 2025 Jun 25. doi: 10.1038/s41375-025-02666-8. Epub ahead of
print.
13. Fresa A, Innocenti I, Tomasso A, Vitale C, Sanna A, Frustaci AM, Visentin A, Romeo
A, Sportoletti P, Giordano A, Perutelli F, Murru R, Mauro FR Hematology, Hematology,
Department of Translational and Precision Medicine, Mosca A, Morelli F, Laureana R,
Galitzia A, Angeletti I, Conte E, Moia R, D'Arena G, Pasquale R, Autore F, Olivieri J,
Stirparo L, Benintende G, Angotzi F, Vuono F, Corbingi A, Del Principe MI, Giannarelli
D, Tedeschi A, Coscia M, Sangiorgi E, Efremov DG, Laurenti L. Familial Forms of
Chronic Lymphocytic Leukemia Have a Worse Prognosis Than Sporadic Forms: an
Italian Case-Control Study. Blood Adv. 2025 Jun 12:bloodadvances.2025016546. doi:
10.1182/bloodadvances.2025016546. Epub ahead of print.
14. Maffioli M, Mora B, Iurlo A, Elli EM, Finazzi MC, Farina M, Rumi E, Caramella M,
Carraro MC, D'Adda M, Molteni A, Mimiola E, Lunghi F, Vismara A, Ubezio M, Di Chio
MC, Anghilieri M, Cattaneo D, Della Porta MG, Bertù L, Coscia M, Passamonti F. The
2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria
Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients. Am J Hematol. 2025
Jun 6. doi: 10.1002/ajh.27734. Epub ahead of print.
15. Serafin A, Cellini A, Martino EA, Mazzetto F, Angotzi F, Frustaci AM, Marchetti M,
Moia R, Sanna A, Riemma C, Cibien F, Noto A, Lista E, Foglietta M, Vitale C, Innao V,
Bullo M, Lovato E, Ferrarini I, Andriola C, Ballotta L, Innocenti I, Fresa A, Favrin G,
Varettoni M, Santambrogio E, Orsucci L, Pasquale R, Moratti M, Laurenti L, Coscia M,
Sportoletti P, Marasca R Prof, Mauro FR Hematology, Hematology, Department of
Translational and Precision Medicine, Patti C, Derenzini E, Scarfò L, Ghia P, Cuneo A,
Tedeschi A, Trentin L Prof, Gentile M, Visentin A. Venetoclax based regimens in
octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter
cohort. Blood Adv. 2025 Apr 16:bloodadvances.2025015818. doi:
10.1182/bloodadvances.2025015818. Epub ahead of print.
16. Durmo R, Chauvie S, Fallanca F, Bergesio F, Pinto A, Del Giudice I, Coscia M,
Corradini P, Angelucci E, Tosi P, Freilone R, Ballerini F, Bari A, Pastore D, Zinzani

7
PLL, Bolis SAM, Flenghi L, Liso A, Olivieri J, Marcheselli L, Merli M, Versari A, Guerra
L, Luminari S. Prognostic role of interim PET in patients with follicular lymphoma: a
post-hoc study of FOLL12 trial by FIL. Blood Adv. 2025 Mar
19:bloodadvances.2024014790. doi: 10.1182/bloodadvances.2024014790. Epub
ahead of print.
17. Innocenti I, Tomasso A, Giannarelli D, Scarfò L, Murru R, Visentin A, Frustaci AM,
Morelli F, Vitale C, Mosca A, Sanna A, Farina G, Laureana R, Gentile M, Galitzia A,
Pasquale R, Autore F, Olivieri J, Romeo A, Deodato M, Stirparo L, Corbingi A, Innao
V, Perutelli F, Martini F, Sportoletti P, Fresa A, Del Principe MI, Tedeschi A, Coscia M,
Ghia P, Laurenti L. Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve
Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.
Hematol Oncol. 2025 Jan;43(1):e70033. doi: 10.1002/hon.70033.
18. Perutelli F, Boccellato E, Montalbano MC, Catania G, Deodato M, Frustaci AM,
Innocenti I, Moia R, Quaglia FM, Quaresmini G, Rivela P, Gaidano G, Krampera M,
Laurenti L, Rambaldi A, Bruno B, Vitale C, Coscia M. Venetoclax therapy in chronic
lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell
transplantation. Br J Haematol. 2025 Jan 7. doi: 10.1111/bjh.19976.
19. Innocenti I, Mosca A, Tomasso A, Galitzia A, Scarfò L, Morelli F, Galli E, Martini F,
Sangiorgi E, Laureana R, Benintende G, Mattiello V, Chiriu S, Del Principe MI,
Zamprogna G, Gentile M, Martino EA, Cappello E, Montalbano MC, Farina G, Innao V,
Stirparo L, Patti C, Sportoletti P, Fresa A, Catania G, Coscia M, Bellesi S, Tedeschi A,
Sanna A, Visentin A, Autore F, Pasquale R, Trentin L, Varettoni M, Ghia P, Murru R,
Laurenti L. Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients
treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life
experience. Hemasphere 2024;8(12):e144. doi: 10.1002/hem3.144.
20. Martino EA, Derudas D, Rossi E, Terlizzi S, Reddiconto G, Stefanoni P, Micozzi J,
Mangiacavalli S, Zamagni E, Offidani M, Furlan A, Buda G, Lotti F, Liberatore C,
Lazzaro A, Pepa RD, Bertuglia G, Barbieri E, Conticello C, De Magistris C, De Paoli L,
Bongarzoni V, Cafro AM, Mele A, Benvenuti P, Cerchione C, Botta C, Antonioli E,
Sgherza N, Aquino S, Mele G, Barilà G, Palmieri S, Annibali O, Bianco R, Febbo MA,
Casaluci GM, Rago A, Fontana R, Farina F, Vigna E, Bruzzese A, Mancuso K, Nappi
D, Morè S, Rivolti E, Califano C, Amendola A, Roccotelli D, Lombardo A, Citro A,
Uccello G, Zambello R, Maggi A, Neri S, Monachesi M, Gozzetti A, Montefusco V,
Brunori M, Cotzia E, Pietrantuono G, Quinto AM, Amico V, Di Renzo N, Coscia M,
Galli M, De Stefano V, Petrucci MT, Neri A, Di Raimondo F, Morabito F, Musto P,
Gentile M. Isatuximab, pomalidomide, and dexamethasone as salvage therapy for
patients with multiple myeloma: the Italian, multicenter, retrospective clinical
experience with 270 cases outside of controlled clinical trials. Haematologica. doi:
10.3324/haematol.2024.286658. Epub ahead of print.
21. Autore F, Visentin A, Deodato M, Vitale C, Galli E, Fresa A, Fazzi R, Sanna A, Olivieri
J, Scortechini I, Del Principe MI, Sportoletti P, Innocenti I, Coscia M, Tedeschi A,
Trentin L Prof, Candoni A, Busca A, Pagano L, Laurenti L. COVID-19 in patients with
Chronic Lymphocytic Leukemia treated with venetoclax: what is the role of anti-CD20
antibody? Blood Adv. 2024. doi: 10.1182/bloodadvances.
22. Chatzikonstantinou T, Scarfò L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J,
Iacoboni G, Demosthenous C, Albi E, Alcoceba M, Al-Shemari S, Aurran-Schleinitz T,
Bacchiarri F, Chatzileontiadou S, Collado R, Davis Z, de Deus Santos MD, Dimou M,
Dmitrieva E, Donaldson D, Dos Santos G, Dreta B, Efstathopoulou M, El-Ashwah S,
Enrico A, Frygier A, Galimberti S, Galitzia A, Gimeno E, Guarente V, Guieze R, Harrop

8
S, Hatzimichael E, Herishanu Y, Hernández-Rivas JÁ, Jaksic O, Kalicińska E, Laribi K,
Karakus V, Kater AP, Kho B, Kislova M, Konstantinou Ε, Koren-Michowitz M,
Kotsianidis I, Kubova Z, Labrador J, Lad D, Laurenti L, Longval T, Lopez-Garcia A,
Marquet J, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R,
Morawska M, Nath UK, Navarro-Bailón A, Olivieri J, Panovska-Stavridis I,
Papaioannou M, Pierie C, Puiggros A, Reda G, Rigolin GM, Ruchlemer R, Schipani M,
Schiwitza A, Shen Y, Shokralla T, Simkovic M, Smirnova S, Soliman DSA,
Stilgenbauer S, Tadmor T, Tomic K, Tse E, Vassilakopoulos T, Visentin A, Vitale C,
Vrachiolias G, Vukovic V, Walewska R, Xu Z, Yagci M, Yañez L, Yassin M, Zuchnicka
J, Oscier D, Gozzetti A, Panagiotidis P, Bosch F, Sportoletti P, Espinet B, Pangalis
GA, Popov VM, Mulligan S, Angelopoulou M, Demirkan F, Papajík T, Biderman B,
Murru R, Coscia M, Tam C, Cuneo A, Gaidano G, Claus R, Stavroyianni N, Trentin L,
Antic D, Smolej L, Kalashnikova OB, Catherwood M, Spacek M, Pospisilova S,
Doubek M, Nikitin E, Chatzidimitriou A, Ghia P, Stamatopoulos K. Therapeutic
strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An
international study of ERIC, the European Research Initiative on CLL. Hemasphere.
2024 Sep 17;8(9):e70004. doi: 10.1002/hem3.70004.
23. Tedeschi A, Frustaci AM, Condoluci A, Coscia M, Chiarle R, Zinzani PL, Motta M,
Gaidano G, Quaresmini G, Scarfò L, Catania G, Deodato M, Jones R, Tabanelli V,
Griggio V, Stüssi G, Calleri A, Pini K, Cairoli R, Zenz T, Signori A, Zucca E, Rossi D,
Montillo M. Atezolizumab, venetoclax, and obinutuzumab combination in Richter
transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm,
phase 2 trial. Lancet Oncol. 2024 Sep 10:S1470-2045(24)00396-6. doi:
10.1016/S1470-2045(24)00396-6.
24. Golovina E, Heizer T, Daumova L, Bajecny M, Fontana S, Griggio V, Jones R, Coscia
M, Riganti C, Savvulidi Vargova K. MiR-155 deficiency and hypoxia results in
metabolism switch in the leukemic B-cells. Cancer Cell Int. 2024 Jul 18;24(1):251. doi:
10.1186/s12935-024-03437-8.
25. Bomben R, Zucchetto A, Laureana R, Chiarenza A, Olivieri J, Tissino E, Rossi FM, Vit
F, Bittolo T, Papotti R, Pozzo F, Gaglio A, Degan M, Polesel J, Marasca R, Visentin A,
Moia R, Innocenti I, Vitale C, Murru R, Varettoni M, Tafuri A, Zaja F, Postorino M,
Martino EA, Condoluci A, Rossi D, Cuneo A, Di Raimondo F, Sportoletti P, Del Giudice
I, Foà R, Mauro FR, Coscia M, Laurenti L, Gaidano G, Trentin L, Principe MID, Gentile
M, Gattei V. CD49d expression is included in a revised 4-factor model predicting
outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A
multicenter real-world experience. Hemasphere. 2024 Jul 15;8(7):e128. doi:
10.1002/hem3.128.
26. Michelerio A, Rubatto M, Roccuzzo G, Coscia M, Quaglino P, Tomasini C.
Eosinophilic Dermatosis of Hematologic Malignancy: Emerging Evidence for the Role
of Insect Bites-A Retrospective Clinico-Pathological Study of 35 Cases. J Clin Med.
2024 May 16;13(10):2935. doi: 10.3390/jcm13102935.
27. Mauro FR, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Frigeri F, Albano
F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C,
Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C,
Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L,
Varettoni M, Pane F, Liberati AM, Merli F, Morello L, Musuraca G, Tani M, Ibatici A,
Regazzoni G, Di Candia M, Palma M, Arienti D, Molica S. Real-World Outcome of
Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic

9
Leukemia: Final Results of the EVIdeNCE Study. Cancers (Basel). 2024 Mar
20;16(6):1228. doi: 10.3390/cancers16061228.
28. Autore F, Visentin A, Deodato M, Vitale C, Galli E, Fresa A, Fazzi R, Sanna A, Olivieri
J, Scortechini I, Del Principe MI, Sportoletti P, Schiattone L, Maschio N, Facchinelli D,
Marchesi F, Coscia M, Tedeschi A, Trentin L, Innocenti I, Candoni A, Busca A,
Pagano L, Laurenti L. Venetoclax infectious risk score to identify patients with chronic
lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter
SEIFEM study. Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27247.
29. Martino EA, Mauro FR, Reda G, Laurenti L, Visentin A, Frustaci A, Vigna E, Pepe S,
Catania G, Loseto G, Murru R, Chiarenza A, Sportoletti P, Del Principe MI, Laureana
R, Coscia M, Galimberti S, Ferretti E, Zucchetto A, Bomben R, Polesel J, Tedeschi A,
Rossi D, Trentin L, Neri A, Morabito F, Gattei V, Gentile M. Ibrutinib as first line
therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective
real-life multicenter Italian cohort. Hematol Oncol. 2024 Jan;42(1):e3249. doi:
10.1002/hon.3249.
30. Vitale C, Griggio V, Perutelli F, Coscia M. CAR-modified Cellular Therapies in Chronic
Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? Hemasphere. 2023
Nov 30;7(12):e988. doi: 10.1097/HS9.0000000000000988.
31. Chatzikonstantinou T, Scarfò L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G,
Kotaskova J, Demosthenous C, Smolej L, Mulligan S, Alcoceba M, Al-Shemari S,
Aurran-Schleinitz T, Bacchiarri F, Bellido M, Bijou F, Calleja A, Medina A, Khan MA,
Cassin R, Chatzileontiadou S, Collado R, Christian A, Davis Z, Dimou M, Donaldson
D, Santos GD, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Fresa A, Galimberti
S, Galitzia A, García-Serra R, Gimeno E, González-Gascón-Y-Marín I, Gozzetti A,
Guarente V, Guieze R, Gogia A, Gupta R, Harrop S, Hatzimichael E, Herishanu Y,
Hernández-Rivas JÁ, Inchiappa L, Jaksic O, Janssen S, Kalicińska E, Kamel L,
Karakus V, Kater AP, Kho B, Kislova M, Konstantinou E, Koren-Michowitz M,
Kotsianidis I, Kreitman RJ, Labrador J, Lad D, Levin MD, Levy I, Longval T, Lopez-
Garcia A, Marquet J, Martin-Rodríguez L, Maynadié M, Maslejova S, Mayor-Bastida C,
Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Murru R, Nath UK, Navarro-
Bailón A, Oliveira AC, Olivieri J, Oscier D, Panovska-Stavridis I, Papaioannou M,
Papajík T, Kubova Z, Phumphukhieo P, Pierie C, Puiggros A, Rani L, Reda G, Rigolin
GM, Ruchlemer R, Daniel de Deus Santos M, Schipani M, Schiwitza A, Shen Y,
Simkovic M, Smirnova S, Abdelrahman Soliman DS, Spacek M, Tadmor T, Tomic K,
Tse E, Vassilakopoulos T, Visentin A, Vitale C, von Tresckow J, Vrachiolias G,
Vukovic V, Walewska R, Wasik-Szczepanek E, Xu Z, Yagci M, Yañez L, Yassin M,
Zuchnicka J, Angelopoulou M, Antic D, Biderman B, Catherwood M, Claus R, Coscia
M, Cuneo A, Demirkan F, Espinet B, Gaidano G, Kalashnikova OB, Laurenti L, Nikitin
E, Pangalis GA, Panagiotidis P, Popov VM, Pospisilova S, Sportoletti P, Stavroyianni
N, Tam C, Trentin L, Chatzidimitriou A, Bosch F, Doubek M, Ghia P, Stamatopoulos K.
Other malignancies in the history of CLL: an international multicenter study conducted
by ERIC, the European Research Initiative on CLL, in HARMONY. EClinicalMedicine.
2023 Nov 15;65:102307. doi: 10.1016/j.eclinm.2023.102307.
32. Vitale C, Griggio V, Todaro M, Riganti C, Jones R, Boccellato E, Perutelli F, Arruga F,
Vaisitti T, Efremov DG, Deaglio S, Landesman Y, Bruno B, Coscia M. Anti-tumor
activity of selinexor in combination with antineoplastic agents in chronic lymphocytic
leukemia. Sci Rep. 2023 Oct 7;13(1):16950. doi: 10.1038/s41598-023-44039-0.
33. Sportoletti P, Laurenti L, Chiarenza A, Gaidano G, Albi E, Mauro FR, Trentin L, Vallisa
D, Pane F, Cuneo A, Albano F, Zamprogna G, Coscia M, Gozzetti A, Reda G, Caira

10
M, Finsinger P, Gualberti G, Iannella E, Malgieri S, Molica S. Patients' preferences for
chronic lymphocytic leukemia treatment: The CHOICE study. Hematol Oncol. 2023.
doi: 10.1002/hon.3216.
34. Visentin A, Chatzikonstantinou T, Scarfò L, Kapetanakis A, Demosthenous C,
Karakatsoulis G; ERIC Group. The evolving landscape of COVID-19 and post-COVID
condition in patients with chronic lymphocytic leukemia: A study by ERIC, the
European research initiative on CLL. Am J Hematol. 2023. doi: 10.1002/ajh.27093.
35. Autore F, Innocenti I, Reda G, Visentin A, Vitale C, Piciocchi A, Fresa A, Leone MMA,
Farina L, Quaresmini G, Baratè C, Giordano A, Ferrari A, Angeletti I, De Paolis MR,
Malerba L, Chiurazzi F, Loseto G, Catania G, Sportoletti P, Scortechini I, Moia R,
Gentile M, Rigolin GM, Mattiello V, Gattei V, Coscia M, Trentin L, Foà R, Cuneo A,
Laurenti L. Lymphadenopathy as a predictor of progression during venetoclax
treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia
study. Hematol Oncol. 2023. doi: 10.1002/hon.3199.
36. Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G,
Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin
GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I,
Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Continuous
venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic
leukemia: A chronic lymphocytic leukemia campus study. Am J Hematol. 2023
Sep;98(9):E237-E240. doi: 10.1002/ajh.27009.
37. Mauro FR; Giannarelli D, Galluzzo CM, Visentin A, Frustaci AM, Sportoletti P, Vitale C,
Reda G, Gentile, Levato L, Murru R, Armiento D, Molinari MC, Proietti G, Pepe S, De
Falco F, Mattiello V, Barabino l, Amici R, Coscia M, Tedeschi A, Girmenia C, Trentin L,
Baroncelli S. Antibody response to the SARS-CoV-2 vaccine and COVID-19
vulnerability during the Omicron pandemic inients with CLL: two-year follow-up of a
multicenter study. Cancers, accepted for publication, 2023.
38. Bonfiglio S, Sutton LA, Ljungström V, Capasso A, Pandzic T, Weström S, Foroughi-Asl
H, Skaftason A, Gellerbring A, Lyander A, Gandini F, Gaidano G, Trentin L, Bonello L,
Reda G, Bödör C, Stavroyianni N, Tam CS, Marasca R, Forconi F, Panayiotidis P,
Ringshausen I, Jaksic O, Frustaci AM, Iyengar S, Coscia M, Mulligan SP, Ysebaert L,
Strugov V, Pavlovsky C, Walewska R, Österborg A, Cortese D, Ranghetti P, Baliakas
P, Stamatopoulos K, Scarfò L, Rosenquist R, Ghia P. BTK and PLCG2 remain
unmutated in one third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023.
doi: 10.1182/bloodadvances.2022008821. Epub ahead of print.
39. Arruga F, Rubin M, Papazoglou D, Iannello A, Ioannou N, Moia R, Rossi D, Gaidano
G, Coscia M, Laurenti L, D'Arena G, Allan JN, Furman RR, Vaisitti T, Ramsay AG,
Deaglio S. The immunomodulatory molecule TIGIT is expressed by chronic
lymphocytic leukemia cells and contributes to anergy. Haematologica 2023. doi:
10.3324/haematol.2022.282177. Epub ahead of print.
40. Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci
L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C,
Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A,
Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A,
Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi
LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A,
Cuneo A, Foà R. High rate of durable responses with undetectable minimal residual
disease with frontline venetoclax and rituximab in young and fit patients with chronic

11
lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II
LLC1518 - 'Veritas' study. Haematologica 2023. doi: 10.3324/haematol.2022.282116.
Epub ahead of print.
41. Visentin A, Mauro FR, Catania G, Fresa A, Vitale C, Sanna A, Mattiello V, Cibien F,
Sportoletti P, Gentile M, Rigolin GM, Quaglia FM, Murru R, Gozzetti A, Molica S,
Marchetti M, Pravato S, Angotzi F, Cellini A, Scarfò L, Reda G, Coscia M, Laurenti L,
Ghia P, Foà R, Cuneo A, Trentin L. Obinutuzumab plus chlorambucil versus ibrutinib
in previously untreated chronic lymphocytic leukemia patients without TP53
disruptions: A real-life CLL campus study. Front Oncol. 2022;12:1033413. doi:
10.3389/fonc.2022.1033413.
42. Levi S, Bronstein Y, Goldschmidt N, Morabito F, Ziv-Baran T, Del Poeta G, Bairey O,
Del Principe MI, Fineman R, Mauro FR, Gutwein O, Reda G, Ruchlemer R, Sportoletti
P, Laurenti L, Shvidel L, Coscia M, Tadmor T, Varettoni M, Aviv A, Murru R, Braester
A, Chiarenza A, Visentin A, Pietrasanta D, Loseto G, Zucchetto A, Bomben R, Olivieri
J, Neri A, Rossi D, Gaidano G, Trentin L, Foà R, Cuneo A, Perry C, Gattei V, Gentile
M, Herishanu Y. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide,
and rituximab in patients with chronic lymphocytic leukemia: A retrospective
multicenter "Real-World" study. Am J Hematol. 2023;98:E24-E27. doi:
10.1002/ajh.26779.
43. Frustaci AM, Del Poeta G, Visentin A, Sportoletti P, Fresa A, Vitale C, Murru R,
Chiarenza A, Sanna A, Mauro FR, Reda G, Gentile M, Varettoni M, Baratè C, Borella
C, Greco A, Deodato M, Zamprogna G, Laureana R, Cipiciani A, Galitzia A, Curto
Pelle A, Morelli F, Malvisi L, Coscia M, Laurenti L, Trentin L, Montillo M, Cairoli R,
Tedeschi A. Coexisting conditions and concomitant medications do not affect
venetoclax management and survival in chronic lymphocytic leukemia. Ther Adv
Hematol. 2022 Oct 10;13:20406207221127550. doi: 10.1177/20406207221127550.
44. Moia R, Dondolin R, De Propris MS, Talotta D, Mouhssine S, Perutelli F, Reda G,
Mattiello V, Rigolin GM, Motta M, Olivieri J, Fanin R, Perbellini O, Ferrarini I, Mauro
FR, Del Giudice I, Laurenti L, Tomasso A, Gentile M, Frustaci AM, Tedeschi A,
Gozzetti A, Stelitano C, Visco C, Moreno C, Forconi F, Marasca R, Coscia M, Rossi D,
Foà R, Gaidano G. Long-term benefit of IGHV mutated patients in a real-life
multicenter cohort of FCR-treated chronic lymphocytic leukemia. Hematol Oncol. 2022.
doi: 10.1002/hon.3080. Epub ahead of print.
45. Antic D, Milic N, Chatzikonstantinou T, Scarfò L, Otasevic V, Rajovic N, Allsup D,
Alonso Cabrero A, Andres M, Baile Gonzales M, Capasso A, Collado R, Cordoba R,
Cuéllar-García C, Correa JG, De Paoli L, De Paolis MR, Del Poeta G, Dimou M,
Doubek M, Efstathopoulou M, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A,
Foglietta M, Lopez-Garcia A, García-Marco JA, García-Serra R, Gentile M, Gimeno E,
da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T,
Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Kater AP, Kersting S,
Koren-Michowitz M, Labrador J, Lad D, Laurenti L, Fresa A, Levin MD, Mayor Bastida
C, Malerba L, Marasca R, Marchetti M, Marquet J, Mihaljevic B, Milosevic I, Mirás F,
Morawska M, Motta M, Munir T, Murru R, Nunes R, Olivieri J, Pavlovsky MA,
Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Reda G, Rigolin GM, Shrestha A,
Šimkovič M, Smirnova S, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Te Raa
D, Tomic K, Tonino S, Trentin L, Van Der Spek E, van Gelder M, Varettoni M, Visentin
A, Vitale C, Vukovic V, Wasik-Szczepanek E, Wróbel T, Segundo LYS, Yassin M,
Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Carrier M, Ghia P,
Stamatopoulos K. Thrombotic and bleeding complications in patients with chronic

12
lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research
Initiative on CLL. J Hematol Oncol. 2022;15:116. doi: 10.1186/s13045-022-01333-0.
46. Scarfò L, Heltai S, Albi E, Scarano E, Schiattone L, Farina L, Moia R, Deodato M,
Ferrario A, Motta M, Reda G, Sancetta R, Coscia M, Rivela P, Laurenti L, Varettoni M,
Perotta E, Capasso A, Ranghetti P, Colia M, Ghia P. Minimal residual disease-driven
treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Blood. 2022;140:2348-2357. doi: 10.1182/blood.2022016901.
47. Perutelli F, Montalbano MC, Boccellato E, Coscia M*, Vitale C*. Beyond ibrutinib:
novel BTK inhibitors for the treatment of chronic lymphocytic leukemia. Curr Opin
Oncol. 2022 Nov 1;34(6):757-767. doi: 10.1097/CCO.0000000000000897.
48. Fresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, Moretti M, Vitale C,
Chiarenza A, Morelli F, Sportoletti P, Marasca R, Sapienza G, Cuccaro A, Murru R,
Sanna A, Patti C, Angeletti I, Coscia M, Trentin L, Pietrasanta D, Innocenti I, Laurenti
L. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic
leukemia: a multicenter Italian study. Blood Adv. 2022;6:3875-3878. doi:
10.1182/bloodadvances.2022006964.
49. Salvetti C, Vitale C, Griggio V, Drandi D, Jones R, Bonello L, Bomben R, Bragoni A,
Bagnara D, Fais F, Gattei V, Cavallo F, Zamò A, Coscia M. Case Report: Sequential
Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal
Relationship and Molecular Insights. Front Oncol. 2022;12:917115. doi:
10.3389/fonc.2022.917115.
50. Marchetti M, Vitale C, Rigolin GM, Vasile A, Visentin A, Scarfò L, Coscia M, Cuneo A.
Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-
World Evidence. J Clin Med. 2022;11:2076. doi: 10.3390/jcm11082076.
51. Perutelli F, Jones R, Griggio V, Vitale C, Coscia M. Immunotherapeutic Strategies in
Chronic Lymphocytic Leukemia: Advances and Challenges. Front Oncol.
2022;12:837531. doi: 10.3389/fonc.2022.837531.
52. Innocenti I, Reda G, Visentin A, Coscia M, Motta M, Murru R, Moia R, Gentile M,
Pennese E, Quaglia FM, Albano F, Cassin R, Deodato M, Ielo C, Frustaci AM,
Piciocchi A, Rughini A, Arena V, Di Sevo D, Tomasso A, Autore F, Del Poeta G,
Scarfò L, Mauro FR, Tedeschi A, Trentin L, Pompili M, Foà R, Ghia P, Cuneo A,
Laurenti L. Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia
patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective
multicentric GIMEMA study. Haematologica. 2022; doi:
10.3324/haematol.2021.280325.
53. Molica S, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A,
Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Moia R, Rigolin GM,
Levato L, Giordano A, Del Poeta G, Stelitano C, Deodato M, Ielo C, Noto A, Guarente
V, Coscia M, Tedeschi A, Gaidano G, Cuneo A, Foa' R, Trentin L, Mauro FR.
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib:
Validation of current prognostic models and development of a simplified three-factor
model. Am J Hematol. 2022;97:E176-E180. doi: 10.1002/ajh.26502.
54. Mauro FR, Paoloni F, Molica S, Reda G, Trentin L, Sportoletti P, Marchetti M,
Pietrasanta D, Marasca R, Gaidano G, Coscia M, Stelitano C, Mannina D, Di Renzo N,
Ilariucci F, Liberati AM, Orsucci L, Re F, Tani M, Musuraca G, Gottardi D, Zinzani PL,
Gozzetti A, Molinari A, Gentile M, Chiarenza A, Laurenti L, Varettoni M, Ibatici A,
Murru R, Ruocco V, Del Giudice I, De Propris MS, Della Starza I, Raponi S, Nanni M,

13
Fazi P, Neri A, Guarini A, Rigolin GM, Piciocchi A, Cuneo A, Foà R. Efficacy of Front-
Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation
in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114
Study. Cancers (Basel). 2021;14:207. doi: 10.3390/cancers14010207.
55. Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D,
Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, Scarfò L, Sportoletti P,
Pravato S, Piazza F, Coscia M, Laurenti L, Molica S, Foà R, Cuneo A, Trentin L.
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted
chronic lymphocytic leukemia: A real-life campus CLL study. Am J Hematol.
2022;97:E95-E99. doi: 10.1002/ajh.26437.
56. Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero
AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S,
Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G,
Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B,
El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H,
Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A,
Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ,
Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova ОB, Kalicińska E,
Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E,
Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro
FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU,
Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I,
Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R,
Saghumyan G, Shrestha A, Šimkovič M, Špaček M, Sportoletti P, Stanca O,
Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van
Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik-Szczepanek E,
Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R,
Cuneo A, Stamatopoulos K, Ghia P. COVID-19 severity and mortality in patients with
CLL: an update of the international ERIC and Campus CLL study. Leukemia.
2021:1–11. doi: 10.1038/s41375-021-01450-8.
57. D’Arena G, Vitale C, Coscia M, Lamorte D, Pietrantuono G, Perutelli F, D’Auria F,
Statuto T, Valvano L, Tomasso A, Griggio V, Jones R, Mansueto G, Villani O,
D’Agostino S, Viglioglia V, De Feo V, Calapai F, Mannucci C, Sgambato A, Efremov
DG, Laurenti L. CD200 Baseline Serum Levels Predict Prognosis of Chronic
Lymphocytic Leukemia. Cancers. 2021; 13:4239. doi: 10.3390/cancers13164239.
58. Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G,
Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V,
Deodato M, Biagi A, Zamprogna G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R,
Fresa A, Cavalloni C, Postorino M, Lelo C, Cairoli R, Di Raimondo F, Montillo M, and
Del Poeta G. Do age, fitness and concomitant medications influence management and
outcomes of CLL patients treated with ibrutinib? Blood Advances 2021, Accepted for
publication.
59. Vitale C, Boccellato E, Comba L, Jones R, Perutelli F, Griggio V, Coscia M. Impact of
Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with
Chronic Lymphocytic Leukemia. Cancers (Basel). 2021;13:3856. doi:
10.3390/cancers13153856.
60. Cuneo A, Rigolin GM, Coscia M, Quaresmini G, Scarfò L, Mauro FR, Motta M, Quaglia
FM, Trentin L, Ferrario A, Laurenti L, Reda G, Ferrari A, Pietrasanta D, Sportoletti P,
Re F, De Paoli L, Foglietta M, Giordano A, Marchetti M, Farina L, Del Poeta G,

14
Varettoni M, Chiurazzi F, Marasca R, Malerba L, Ibatici A, Tisi MC, Stefoni V, Leone
M, Baratè C, Olivieri J, Murru R, Gentile M, Sanna A, Gozzetti A, Gattei V, Gottardi D,
Derenzini E, Levato L, Orsucci L, Penna G, Chiarenza A, Foà R. Management of
chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic
and at the start of the vaccination program. A Campus CLL report. Hematol Oncol.
2021 Jul 13. doi: 10.1002/hon.2899. [Epub ahead of print].
61. Mauro FR, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A,
Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Rigolin GM, Levato L,
Giordano A, Del Poeta G, Stelitano C, Ielo C, Noto A, Guarente V, Molica S, Coscia M,
Tedeschi A, Gaidano G, Cuneo A, Foà R, Martelli M, Girmenia C, Gentile G, Trentin L.
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic
Leukemia Treated with Ibrutinib. Cancers (Basel). 2021;13:3240. doi:
10.3390/cancers13133240.
62. Vitale C, Griggio V, Riganti C, Todaro M, Kopecka J, Jones R, Salvetti C, Boccellato
E, Perutelli F, Voena C, Godio L, Boccadoro M, Coscia M. Targeting HIF-1α
Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions
in CLL. Cancers (Basel). 2021;13:2883. doi: 10.3390/cancers13122883.
63. Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M,
Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A,
Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Recchia AG, Rossi FM,
Zucchetto A, Al-Janazreh H, Martino EA, Vigna E, Tripepi G, D'Arrigo G, Galimberti S,
Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G,
Jaksic O, Olivieri J, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin
L, Foà R, Ferrarini M, Gattei V, Gentile M. TP53 disruption as a risk factor in the era of
targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic
leukemia cases. Am J Hematol. 2021 ;96:E306-E310. doi: 10.1002/ajh.26235.
64. Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L,
Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A,
Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM,
Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Cassin R, D Arrigo G, Galimberti S,
Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P,
Menichini P, Olivieri J, Cutrona G, Rossi D, Cuneo A, Di Raimondo F, Gaidano G,
Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Effectiveness of ibrutinib
as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison
with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. Am
J Hematol. 2021;96:E269-E272. doi: 10.1002/ajh.26201.
65. Dogliotti I, Ragaini S, Vassallo F, Boccellato E, De Luca G, Perutelli F, Boccomini C,
Clerico M, Botto B, Grimaldi D, Orsucci L, Ferrero S, Vitale C, Ferrero D, Coscia M,
Cavallo F. Real Life Use of Bendamustine in Elderly Patients with Lymphoid
Neoplasia. J Pers Med. 2021;11:249. doi: 10.3390/jpm11040249.
66. Rigolin GM, Cavazzini F, Piciocchi A, Arena V, Visentin A, Reda G, Zamprogna G,
Cibien F, Vitagliano O, Coscia M, Farina L, Gaidano G, Murru R, Varettoni M, Paolini
R, Sportoletti P, Pietrasanta D, Molinari AL, Quaglia FM, Laurenti L, Marasca R,
Marchetti M, Mauro FR, Crea E, Vignetti M, Gentile M, Montillo M, Foà R, Cuneo A;
GIMEMA group. Efficacy of idelalisib and rituximab in relapsed/refractory chronic
lymphocytic leukemia outside of clinical trials. A report of the GIMEMA WORKING
GROUP. Hematol Oncol. 2021;39(3):326-335. doi: 10.1002/hon.2861.

15
67. Vitale C, Salvetti C, Griggio V, Porrazzo M, Schiattone L, Zamprogna G, Visentin A,
Vassallo F, Cassin R, Rigolin GM, Murru R, Laurenti L, Rivela P, Marchetti M,
Pennese E, Gentile M, Boccellato E, Perutelli F, Montalbano MC, De Paoli L, Reda G,
Orsucci L, Trentin L, Cuneo A, Tedeschi A, Scarfò L, Gaidano G, Mauro FR, Foà R,
Boccadoro M, Coscia M. Pre-existing and treatment-emergent autoimmune cytopenias
in patients with CLL treated with targeted drugs. Blood 2021;137(25):3507-3517. doi:
10.1182/blood.2020008201.
68. Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L,
Coscia M, Herishanu Y, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A,
Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A,
Vigna E, Martino EA, Mendicino F, Botta C, Caracciolo D, Cassin R, D'Arrigo G,
Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G,
Cutrona G, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà
R, Ferrarini M, Gattei V, Gentile M. Assessment of the 4-factor score: Retrospective
analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. Am J Hematol.
2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127.
69. Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J,
Crespo M, Coscia M, Vitale C, Böttcher S, Weppner G, Ritgen M, Stilgenbauer S,
Tausch E, Fischer K, Hallek M, Eichhorst B, Brüggemann M, Herling CD. B-cell Acute
Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with
Lenalidomide. Blood. 2021;137(16):2267-2271. doi: 10.1182/blood.2020008609..
70. Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L,
Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A,
Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM,
Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Mendicino F, Cassin R, D'Arrigo G,
Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G,
Monti P, Menichini P, Cutrona G, Jaksic O, Rossi D, Di Raimondo F, Cuneo A,
Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Comparison
of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic
lymphocytic leukemia cases. Eur J Haematol. 2021 Apr;106(4):493-499. doi:
10.1111/ejh.13573.
71. Mauro FR, Giannarelli D, Galluzzo DM, Vitale C, Visentin A, Riemma C, Rosati S,
Porrazzo M, Pepe S, Gentile M, Coscia M, Trentin L, Micozzi A, Gentile G, Baroncelli
S. Response to conjugate pneumococcal vaccine (PCV-13) in patients with chronic
lymphocytic leukemia (CLL). Leukemia, 2021;35:737-746. doi: 10.1038/s41375-020-
0884-z. Epub 2020 Jun 17.
72. Gentile M, Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L,
Coscia M, Herishanu Y, Recchia AG, Varettoni M, Murru R, Chiarenza A, Condoluci A,
Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A,
Fraticelli V, Vigna E, Botta C, Tripepi G, Arrigo G, Rago A, Angeletti I, Biagi A, Del
Giudice I, Bomben R, Rigolin GM, Rossi D, Di Raimondo F, Gaidano G, Polliack A,
Cuneo A, Foà R, Gattei V. Survival risk score for real-life relapsed/refractory chronic
lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia.
2021;35:235-238. doi: 10.1038/s41375-020-0833-x.
73. Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, Coscia M.
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic
Lymphocytic Leukemia. Front Immunol. 2020;11:594556. doi:
10.3389/fimmu.2020.594556.

16
74. Coscia M, Bruno B, Neelapu S. Editorial: CAR T-Cell Therapies in Hematologic
Tumors. Front Oncol. 2020;10:588134. doi: 10.3389/fonc.2020.588134.
75. Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel
JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr
PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS,
Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci
F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de
la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M,
Foà R, Ghia P; GIMEMA, European Research Initiative (ERIC) on CLL, US study
group. Efficacy of bendamustine and rituximab in unfit patients with previously
untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-
world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 ;9(22):8468-8479.
doi: 10.1002/cam4.3470.
76. Gentile M, Martino EA, Visentin A, Coscia M, Reda G, Sportoletti P, Mauro FR,
Laurenti L, Varettoni M, Murru R, Chiarenza A, Vigna E, Mendicino F, Lucia E, Bossio
S, Recchia AG, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM,
Zucchetto A, Al-Janazreh H, Vitale C, Tripepi G, D'Arrigo G, Angeletti I, Bomben R,
Neri A, Cutrona G, Fronza G, Di Raimondo F, Gaidano G, Cuneo A, Foà R, Ferrarini
M, Trentin L, Gattei V, Morabito F. Validation of a survival-risk score (SRS) in
relapsed/refractory CLL patients treated with idelalisib-rituximab. Blood Cancer J.
2020;10:92. doi: 10.1038/s41408-020-00358-3.
77. Apolito V, Giaccone L, Ferrero S, Larocca A, Cavallo F, Coscia M, Beggiato E, Butera
S, Martella F, Dainese C, Cetani G, Scaldaferri M, Cattel F, Boccadoro M, Ferrero D,
Bruno B, Cerrano M. Netupitant-palonosetron to prevent chemotherapy-induced
nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and
autologous stem cell transplantation. Ann Hematol. 2020;99:2197-2199. doi:
10.1007/s00277-020-04180-6.
78. Farina L, Barretta F, Scarfò L, Bruno B, Patriarca F, Frustaci AM, Coscia M, Salvetti C,
Quaresmini G, Fanin R, Onida F, Magagnoli M, Zallio F, Vallisa D, Reda G, Ferrario A,
Corradini P, Montillo M. Refractory and 17p-deleted chronic lymphocytic leukemia:
improving survival with pathway inhibitors and allogeneic stem cell transplantation. Biol
Blood Marrow Transplant. 2020;26:e256-e262. doi: 10.1016/j.bbmt.2020.06.032.
79. Porrazzo M, Nicolai E, Riminucci M, Vitale C, Coscia M, De Paoli L, Rago A,
Buscicchio G, Maestrini G, Ligia S, Di Prima A, Corsi A, Caronna R, Gaidano G,
Mauro FR. Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic
Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. Cancers (Basel).
2020;12:1773. doi: 10.3390/cancers12071773.
80. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-
Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G,
Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S,
Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L,
Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe
E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G,
Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting
S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G,
Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A,
Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N,
Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M,
Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P.

17
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint
study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Leukemia. 2020;34:2354-2363. doi: 10.1038/s41375-020-0959-x.
81. Cerrano M, Ruella M, Perales M, Vitale C, Faraci G, Giaccone L, Coscia M, Maloy M,
Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. The Advent of
CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research into
Clinical Practice. Front Immunol. 2020;11:888. doi: 10.3389/fimmu.2020.00888.
eCollection 2020.
82. Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-Szczepanek E,
Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M,
Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L,
Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meûter A, Dimou M,
Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L,
Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou
M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel
MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry
C, Levi S, Polliack A, Ghia P. Frontline treatment with the combination obinutuzumab ±
chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a
multinational, multicenter study by ERIC and the Israeli CLL study group. Am J
Hematol. 2020 Jun;95(6):604-611. Am J Hematol. 2020;95:604-611. doi:
10.1002/ajh.25766.
83. Mauro FR, Molica S, Soddu S, Ilariucci F, Coscia M, Zaja F, Angelucci E, Re F,
Liberati AM, Tedeschi A, Reda G, Pietrasanta D, Gozzetti A, Battistini R, Del Poeta G,
Musolino C, Nanni M, Piciocchi A, Vignetti M, Neri A, Albano F, Cuneo A, Del Giudice
I, Della Starza I, De Propris MS, Raponi S, Guarini AR, Foà R. High rate of MRD-
responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia
treated with front-line fludarabine, cyclophosphamide, and intensified dose of
ofatumumab (FCO2). Haematologica. 2020;105:235705. doi:
10.3324/haematol.2019.235705.
84. Vitale C, Montalbano MC, Salvetti C, Boccellato E, Griggio V, Boccadoro M, Coscia M.
Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted
Drugs. Cancers (Basel). 2020;12:282. doi: 10.3390/cancers12020282.
85. Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Bo MD,
Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA,
Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R,
Massaia M, Boccadoro M, Coscia M. HIF-1α is over-expressed in leukemic cells from
TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic
leukemia. Haematologica. 2020;105:1042-1054. doi: 10.3324/haematol.2019.217430.
86. Arruga F, Bracciamà V, Vitale N, Vaisitti T, Gizzi K, Yeomans A, Coscia M, D'Arena G,
Gaidano G, Allan JN, Furman RR, Packham G, Forconi F, Deaglio S. Bidirectional
linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and
in Richter's syndrome: therapeutic implications. Leukemia. 2020;34:462-477. doi:
10.1038/s41375-019-0571-0.
87. Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A, Spina V, Terzi-
di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Favini S, Sagiraju S, Jabangwe C,
Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F,
Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M,
Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton

18
P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL,
Catherwood M, Deaglio S, Foà R, Gaidano G, Rossi D. Biological and clinical
implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica
2020;105(2):448-456.
88. Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM,
Piazza F, Cesini L, Tedeschi A, Laurenti L, Cassin R, Coscia M, Cuneo A, Foà R,
Semenzato G, Trentin L. A scoring system to predict the risk of atrial fibrillation in
chronic lymphocytic leukemia. Hematol Oncol. 2019;37:508-512. doi:
10.1002/hon.2655.
89. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M,
Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S,
Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale
C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L. Elevated
Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients
Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Cancers (Basel).
2019;11:896. doi: 10.3390/cancers11070896.
90. D’Arena G, Valvano L, Vitale C, Coscia M, Statuto T, Bellesi S, Lamorte D, Musto P,
Laurenti L, D’Auria F. CD200 and prognosis in chronic lymphocytic leukemia:
conflicting results. Leuk Res 2019;83:106169. doi: 10.1016/j.leukres.2019.106169..
91. Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L,
Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Coscia M, Sportoletti P,
Murru R, Levato L, Gentile M, D'Arena G, Villa MR, Fontana R, Efremov D, Tedeschi
A, Scarfò L, Cuneo A, Foà R, Laurenti L. Venetoclax in CLL patients who progress
after B-cell Receptor inhibitor treatment: a retrospective multicentric Italian experience.
Br J Haematol 2019; 187(1):e8-e11. doi: 10.1111/bjh.16123.
92. Coscia M, Vitale C, Cerrano M, Maffini E, Giaccone L, Boccadoro M, Bruno B.
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and
future perspectives. Front Biosci (Landmark Ed) 2019;24:1284-1315. doi:
10.2741/4780.
93. Italian Association for the Study of the Liver (AISF), Angelucci E, Astegiano M,
Baratelli C, Biancone L, Bironzo P, Brancaccio G, Brunetto MR, Bruno R, Burra P,
Cabras MG, Caraceni P, Chialà C, Clemente MG, Colli A, Daniele B, De Gasperi E, Di
Marco V, Ditto MC, Fagiuoli S, Ferri C, Gaeta GB, Grossi PA, Imperatrice B,
Lampertico P, Macaluso FS, Madonia S, Marignani M, Mazzarelli C, Mella A, Missale
G, Parisi S, Pasulo L, Puoti M, Rendina M, Ribaldone D, Rossi G, Toniutto P, Tucci A,
Vajro P, Viganò M, Volpes R, Zignego AL, Giannini EG, Miele L, Russo FP, Petta S,
Bonora S, Brignardello E, Busca A, Cariti G, Cavallo F, Conforti M, Coscia M, Craxì A,
Curci D, Cusinato S, Di Maio M, Valle RD, Fusaro E, Giacardi A, Giaccone L, Lagget,
M, Libertucci D, Minutolo R, Montrucchio G, Orlando A, Orsucci L, Pasquina C, Pera
A, Peroni CL, Pirisi M, Racca P, Riccardini F, Rizzett0 M, Salizzoni M, Salomone M,
Saracco GM, Scaglione L, Torre G, Tozzi R, Vitolo U, Verme G. AISF position paper
on HCV in immunocompromised patients. Digestive and Liver Disease 2019;51:10-23.
doi:10.1016/j.dld.2018.09.022.
94. Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N,
Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M,
Tedeschi A, Stavroyianni N, Muzio M, Stamatopoulos K, Ghia P. Dichotomous Toll-like
receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
D'Arena G, Valvano L, Vitale C, Coscia M, Statuto T, Bellesi S, Lamorte D, Musto P,

19
Laurenti L, D'Auria F. CD200 and prognosis in chronic lymphocytic leukemia:
Conflicting results. Leuk Res. 2019 Jun 11;83:106169. doi:
10.1016/j.leukres.2019.106169.
95. D'Arena G, Vitale C, Coscia M, D'Auria F, Bellesi S, Topini G, Panichi V, Valvano L,
Statuto T, Corrente F, Laurenti L. External validation of the accuracy of 'CLLflow
score'. J Investig Med. 2018;66:e6. doi: 10.1136/jim-2018-000832.
96. Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI,
Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S,
Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG,
Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del
Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R,
Morabito F. Predictive value of the CLL-IPI in CLL patients receiving chemo-
immunotherapy as first-line treatment. Eur J Haematol. 2018. doi:10.1111/ejh.13149.
[Epub ahead of print].
97. Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Medina Perez A,
Coscia M, Laurenti L, Musuraca G, Farina L, Rivas Delgado A, Orlandi EM, Galieni P,
Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V,
Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S,
Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti
M, de la Serna J, Moreno C, Foà R, Ghia P. Efficacy of bendamustine and rituximab
as first salvage treatment in chronic lymphocytic leukemia and indirect comparison
with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica.
2018;103:1209-1217. doi: 10.3324/haematol.2018.189837.
98. D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L,
Ciolli S, Gilestro M, Molica S, Bellesi S, Giuseppe T, Valentina P, Autore F, Innocenti I,
Musto P, Deaglio S, Laurenti L, Del Vecchio L. CD200 included in a 4-marker modified
Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic
lymphocytic leukaemia. Hematol Oncol. 2018. doi: 10.1002/hon.2510. [Online ahead
of print].
99. Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe
MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A,
Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G,
Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G,
Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.
Validation of a biological score to predict response in chronic lymphocytic leukemia
patients treated front-line with bendamustine and rituximab. Leukemia. 2018
Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6.
100. D'Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V, Caraglia M,
Calapai G, Laurenti L, Musto P, Di Minno G, Fenoglio D. Regulatory T Cells and Their
Prognostic Relevance in Hematologic Malignancies. J Immunol Res.
2017;2017:1832968.
101. D'Arena G, Vitale C, Perbellini O, Coscia M, La Rocca F, Ruggieri V, Visco C, Di
Minno NMD, Innocenti I, Pizza V, Deaglio S, Di Minno G, Giudice A, Calapai G, Musto
P, Laurenti L, Iorio EL. Prognostic relevance of oxidative stress measurement in
chronic lymphocytic leukaemia. Eur J Haematol. 2017; 99:306-314.
102. Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G,
D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B,
Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D,

20
Liberati AM, Russo F, Foa' R. Chlorambucil plus rituximab as front-line therapy for
elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-
based risk stratification. Haematologica. 2017;102:e352-e355.
103. Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, Bernocco E,
Monitillo L, Cerri M, Ruggeri M, Omede P, Deambrogi C, De Paoli L, Passera R,
Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, Ferrero S.
Progressive telomere shortening is part of the natural history of chronic lymphocytic
leukaemia and impacts clinical outcome: evidences from long term follow-up. Br J
Haematol. 2018;181:693-695.
104. Vitale C, Griggio V, Todaro M, Salvetti C, Boccadoro M, Coscia M. Magic pills: new
oral drugs to treat chronic lymphocytic leukemia. Expert Opin Pharmacother.
2017;18(4):411-425.
105. Arruga F, Gizdic B, Bologna C, Cignetto S, Buonincontri R, Serra S, Vaisitti T, Gizzi
K, Vitale N, Garaffo G, Mereu E, Diop F, Neri F, Incarnato D, Coscia M, Allan J, Piva
R, Oliviero S, Furman RR, Rossi D, Gaidano G, Deaglio S. Mutations in NOTCH1
PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia
cells by modulating the tumor suppressor gene DUSP22. Leukemia. 2017;31(9):1882-
1893.
106. Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra s, Castella B, Peola S,
Foglietta M, Drandi D, Omedé P, Sblattero D, Cappello P, Chiarle R, Deaglio S,
Boccadoro M, Novelli F, Massaia M and Coscia M. Humoral immune responses
toward tumor-derived antigens in previously untreated patients with chronic
lymphocytic leukemia. Oncotarget. 2017; 8:3274-3288.
107. Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, Brusa D, Coscia
M, Jaksic O, Inghirami G, Rossi D, Furman RR, Robson SC, Gaidano G, Chiorazzi N,
Deaglio S. Adenosine signaling mediates hypoxic responses in the chronic
lymphocytic leukemia microenvironment. Blood Advances. 2016; 1:47-61.
108. Gentile M, Zirlik K, Ciolli S, Mauro FR, Di Renzo N, Mastrullo L, Angrilli F, Molica S,
Tripepi G, Giordano A, Di Raimondo F, Selleri C, Coscia M, Musso M, Orsucci L,
Mannina D, Rago A, Giannotta A, Ferrara F, Herishanu Y, Shvidel L, Tadmor T,
Scortechini I, Ilariucci F, Murru R, Guarini A, Musuraca G, Mineo G, Vincelli I, Arcari A,
Tarantini G, Caparrotti G, Chiarenza A, Levato L, Villa MR, De Paolis MR, Zinzani PL,
Polliack A, Morabito F. Combination of bendamustine and rituximab as front-line
therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective
clinical practice experience with 279 cases outside of controlled clinical trials. Eur J
Cancer. 2016; 60:154-65.
109. Laurenti L, Autore F, Innocenti I, D'Arena G, Coscia M, Mondello P, Chiusolo P,
Bellesi S, Efremov DG, Sica S, Mauro FR. Autoimmune hemolytic anemia during
bendamustine plus rituximab treatment in CLL patients: multicenter experience. Leuk
Lymphoma. 2016; 27:1-3.
110. Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, Pagnani A,
Coscia M, D'Arena G, Mereu E, Piva R, Furman RR, Rossi D, Gaidano G, Terhorst C,
Deaglio S. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient
response. J Clin Invest. 2016; 126:181-94.
111. Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C,
Ferracini R, Saraci E, Omedé P, Riganti C, Palumbo A, Boccadoro M, Massaia M.
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-

21
targetable microenvironment-induced immune suppression in human myeloma.
Oncoimmunology. 2015; 4:e1047580.
112. Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A,
Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D,
Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M. A
phase II multi-center trial of Pentostatine pluc Cyclophosphamide with Ofatumumab in
older previoulsy untreate chronic lymphocytic leukemia patients. Haematologica. 2015.
100:501-4.
113. Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella
B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M,
Coscia M. Simvastatin and downstream inhibitors circumvent constitutive and stromal
cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Oncotarget.
2015; 6:29833-46.
114. Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian
P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del
Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A,
Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M,
Cuneo A, Gattei V, Foà R, Gaidano G. Molecular prediction of durable remission after
first line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic
leukemia.Blood. 2015; 126:1921-4.
115. Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F,
Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M,
Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R.
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic
leukemia (CLL) and progressive disease. Leukemia. 2015; 29:1360-5.
116. Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R,
Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Garcia JG, Wolberger C, Raffaelli
N, Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT)
promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood. 2015;
125:111-23.
117. Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A,
Zucchetto A, Tissino E, Vitale C, Coscia M, Usai C, Pepper C, Gattei V, Bruzzone S,
Deaglio S. The enzymatic activities of CD38 enhance CLL growth and trafficking:
implications for therapeutic targeting. Leukemia 2015; 29:356-68.
118. Foglietta M, Castella B, Mariani S, Coscia M, Godio L, Ferracini R, Ruggeri M,
Muccio V, Omedé P, Palumbo A, Boccadoro M, Massaia M. The bone marrow of
myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory
T cells irrespectiveof the disease status. Haematologica. 2014; 99:1605-10.
119. Montillo M, Tedeschi A, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N,
Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E,
Massaia M. Bendamustine and subcutaneous alemtuzumab combination is an
effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
Haematologica. 2014; 99:159-61.
120. Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D'Arena G,
Coscia M, Laurenti L, Forconi F, Gaidano G, Mingari MC, Moretta L, Malavasi F,
Deaglio S. HLA-G is a component of the chronic lymphocytic leukemia escape

22
repertoire to generate immune suppression: impact of the HLA-G 14 base pair
(rs66554220) polymorphism. Haematologica. 2014; 99:888-96.
121. Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A,
Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Piciocchi A, Vignetti M, Fazi
P, Gentile G, De Propris MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I,
Nanni M, Albano F, Cuneo A, Guarini A, Foà R; Gruppo Italiano Malattie Ematologiche
dell’Adulto Working Party for Chronic Lymphoproliferative Disorders. Fludarabine plus
alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic
leukemia (CLL) and an adverse biologic profile. Leuk Res. 2014; 38:198-203.
122. Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M, Laurenti L, D'Arena G,
Jaksic O, Inghirami G, Rossi D, Gaidano G, Deaglio S. Functional impact of NOTCH1
mutations in chronic lymphocytic leukemia. Leukemia. 2014; 28:1060-70.
123. D'Arena G, Laurenti L, Coscia M, Cortelezzi A, Chiarenza A, Pozzato G, Vigliotti
ML, Nunziata G, Fragasso A, Villa MR, Grossi A, Selleri C, Deaglio S, La Sala A, Del
Poeta G, Simeon V, Aliberti L, De Martino L, Giudice A, Musto P, De Feo V.
Complementary and alternative medicine use in patients with chronic lymphocytic
leukemia: an Italian multicentric survey. Leuk Lymphoma. 2014; 55:841-7.
124. Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G,
Inghirami G, Gaidano G, Malavasi F, Deaglio S. The PD-1/PD-L1 axis contributes to T-
cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013; 98:953-63.
125. Coscia M, Vitale C, Peola S, Foglietta M, Rigoni M, Griggio V, Castella B, Angelini
D, Chiaretti S, Riganti C, Guarini A, Drandi D, Ladetto M, Bosia A, Foà R, Battistini L,
Boccadoro M, Fournié JJ, Massaia M. Dysfunctional Vγ9Vδ2 T cells are negative
prognosticators and markers of dysregulated mevalonate pathway activity in chronic
lymphocytic leukemia cells. Blood. 2012; 120:3271-9.
126. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, D'Arena G, Coscia
M, Tripodo C, Inghirami G, Robson SC, Gaidano G, Malavasi F, Deaglio S. CD73-
generated extracellular adenosine in chronic lymphocytic leukemia creates local
conditions counteracting drug-induced cell death. Blood. 2011; 118:6141-52.
127. Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, Foglietta M,
Palumbo A, Bosia A, Coscia M, Boccadoro M, Massaia M. Immune modulation by
zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T
cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells. J Immunol. 2011;
187:1578-90.
128. Castella B, Vitale C, Coscia M, Massaia M. Vγ9Vδ2 T cell-based immunotherapy in
hematological malignancies: from bench to bedside. Cell Mol Life Sci. 2011; 68:2419-
32.
129. Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B, Foglietta
M, Griggio V, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M. IGHV
unmutated CLL B cells are more prone to spontaneous apoptosis and subject to
environmental prosurvival signals than mutated CLL B cells. Leukemia. 2011; 25:828-
37.
130. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I,
Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M.
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary
carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010; 14:2803-
15.

23
131. Mariani S, Hwang SY, Foglietta M, Bonello L, Vitale C, Coscia M, Fiore F, Bruno B,
Massaia M. Comprehensive assessment of the TCRBV repertoire in small T-cell
samples by means of an improved and convenient multiplex PCR method. Exp
Hematol. 2009; 37:728-38.
132. Biragyn A, Coscia M, Nagashima K, Sanford M, Young HA, Olkhanud P. Murine
beta-defensin 2 promotes TLR-4/MyD88-mediated and NF-kappaB-dependent atypical
death of APCs via activation of TNFR2. J Leukoc Biol. 2008; 83:998-1008.
133. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M,
Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P,
de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S,
Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G.
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective
pharmacologic profile competitive with bortezomib. Blood. 2008; 111:2765-75.
134. Matta GM, Battaglio S, Dibello C, Napoli P, Baldi C, Ciccone G, Coscia M,
Boccadoro M, Massaia M. Polyclonal immunoglobulin E levels are correlated with
hemoglobin values and overall survival in patients with multiple myeloma. Clin Cancer
Res. 2007; 13:5348-54.
135. Fiore F, Nuschak B, Peola S, Mariani S, Muraro M, Foglietta M, Coscia M, Bruno B,
Boccadoro M, Massaia M. Exposure to myeloma cell lysates affects the immune
competence of dendritic cells and favors the induction of Tr1-like regulatory T cells.
Eur J Immunol. 2005;35: 1155-63.
136. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M,
Palumbo A, Coscia M, Castella B, Bruno B, Bertieri R, Boano L, Boccadoro M,
Massaia M. Effector gammadelta T cells and tumor cells as immune targets of
zoledronic acid in multiple myeloma. Leukemia. 2005; 19:664-70.
137. Coscia M, Biragyn A. Cancer immunotherapy with chemoattractant peptides. Semin
Cancer Biol. 2004; 14:209-18.
138. Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, Baskar S, Wang JM,
Kwak LW. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently
into the class II processing pathway in vitro and induces protective immunity in vivo.
Blood. 2004; 104:1961-9.
139. Coscia M, Kwak LW. Therapeutic idiotype vaccines in B lymphoproliferative
diseases. Expert Opin Biol Ther. 2004; 4:959-63.
140. Ruffini PA, Biragyn A, Coscia M, Harvey LK, Cha SC, Bogen B, Kwak LW. Genetic
fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger
antitumor immunity independent of chemotaxis. J Leukoc Biol. 2004; 76:77-85.
141. Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A,
Boccadoro M, Massaia M. Long-term follow-up of idiotype vaccination in human
myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia. 2004;
18:139-45.
142. Mariani S, Coscia M, Even J, Peola S, Foglietta M, Boccadoro M, Sbaiz L,
Restagno G, Pileri A, Massaia M. Severe and long-lasting disruption of T-cell receptor
diversity in human myeloma after high-dose chemotherapy and autologous peripheral
blood progenitor cell infusion. Br J Haematol. 2001; 113:1051-9.
143. Besostri B, Beggiato E, Bianchi A, Mariani S, Coscia M, Peola S, Foglietta M,
Boccadoro M, Pileri A, Moretta L, Massaia M. Increased expression of non-functional

24
killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. Br J Haematol.
2000; 109:46-53.
144. Coscia M, Massaia M. Active specific immunotherapy in human myeloma after high-
dose chemotherapy. Reviews in Clinical and Experimental Hematology. 1999; 9:40-56.
145. Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C,
Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M,
Pileri A. Idiotype vaccination in human myeloma: generation of tumor-specific immune
responses after high-dose chemotherapy. Blood. 1999; 94:673-83.
ADDITIONAL IN EXTENSO PUBLICATIONS
1. Vitale C, Coscia M. Aspetti biotecnologici delle immunoterapie con cellule CAR T.
Progressi in Ematologia/1 2019.
2. Salvetti C, Santambrogio E, Orsucci L, Vitolo U, Coscia M, Vitale C. Idelalisib nei
pazienti con leucemia linfatica cronica e linfoma follicolare: esperienza
monocentrica real life. Eur J Oncol. 2017;22(1-S):11-16.
3. Vitale C, Coscia M. Trattamento con idelalisib e rituximab di un paziente con
leucemia linfatica cronica e anemia emolitica autoimmune refrattaria. Quaderni di
Ematologia clinica. Anno IV – Numero 1/2016.
4. Massaia M, Fiore F, Castella B, Pantaleoni F, Mariani S, Peola S, Hwang SY,
Matta G, Foglietta M, Coscia M, Boccadoro M. Unconventional properties of
zoledronic acid. Haematologica Reports. 2006; 2(7):106-108.
5. Mariani S, Pantaleoni F, Peola S, Hwang SY, Castella B, Matta G, Foglietta
M, Fiore F, Coscia M, Boccadoro M, Massaia M. Distribution of γδ T cells in patients
with hematological malignancies. Haematologica Reports. 2006; 2(3):32-34.
6. Coscia M, Quaglino E, Curcio C, Pantaleoni F, Forni G, Massaia M.
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the
Her-2/neu oncogene. Haematologica Reports 2006; 2(3):37-38.
7. Coscia M, Massaia M. Active specific immunotherapy in human myeloma
after high-dose chemotherapy. Reviews in Clinical and Experimental Hematology.
1999; 9:40-56.
Bibliography
- Author or co-author in 145 peer-reviewed articles and 7 in extenso publications.
- Coauthor in ≈180 abstracts at National and International meetings and conferences.
- Speaker at >90 National and International meetings and conferences (including the
Annual Meeting and Exposition of the American Society of Hematology, the
Congress of the European Haematology Association and the Congress of the Italian
Society of Hematology).
- H Index: 36 (source: Scopus)
- Total N. of citations: >4300 (source: Scopus)

Varese, March 31st, 2026

Dr. Marta Coscia